Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGISTER study of mutation-guided imatinib dosing in advanced GIST
ACTRN12608000392369Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of imatinib and nilotinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Time to ultimate disease progression in the exon 9/wild-type subgroup. Started Dec 2008; status: completed.
02
Drugs
imatinibnilotinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ACTRN12608000392369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000392369.